|
Originally published In Press as doi:10.1074/jbc.M111551200 on February 4, 2002
J. Biol. Chem., Vol. 277, Issue 16, 14221-14226, April 19, 2002
8-Isoprostaglandin E2 Enhances Receptor-activated
NF B Ligand (RANKL)-dependent Osteoclastic Potential
of Marrow Hematopoietic Precursors via the cAMP Pathway*
Yin
Tintut §,
Farhad
Parhami ,
Anastasia
Tsingotjidou¶,
Sotirios
Tetradis¶,
Mary
Territo , and
Linda L.
Demer
From the Departments of Medicine and
Physiology, School of Medicine and ¶ Department of Oral
Radiology, School of Dentistry, UCLA,
Los Angeles, California 90095
Lipid oxidation products promote atherosclerosis
and may also affect osteoporosis. We showed previously that oxidized
lipids including 8-isoprostaglandin E2 (isoPGE2) inhibit osteoblastic differentiation of preosteoblasts. Since osteoporosis is mediated both
by decreased osteoblastic bone formation and by increased osteoclastic
bone resorption, we assessed whether oxidized lipids regulate the
osteoclastic potential of marrow hematopoietic cells. Treatment of
marrow-derived preosteoclasts with isoPGE2 enhanced osteoclastic
differentiation as evidenced by increased tartrate-resistant acid
phosphatase (TRAP) activity and multinucleation, which were inhibited
by calcitonin, and increased numbers of resorption pits. The enhanced
osteoclastic differentiation by isoPGE2 was observed whether
preosteoclasts were in coculture with stromal cells or in
monoculture in the presence of receptor-activated NF B ligand (RANKL)
and macrophage colony-stimulating factor. Receptor antagonist studies
suggest that isoPGE2 effects were mediated by prostaglandin receptor
subtypes EP2/DP on preosteoclasts and subtype EP1 and thromboxane
receptors on stromal/osteoblast cells. The enhanced TRAP activity was
also inhibited by cAMP-dependent protein kinase inhibitors,
and isoPGE2 elevated intracellular cAMP levels of preosteoclast
monocultures. Other oxidized lipids also enhanced the TRAP activity of
preosteoclast monocultures. These data suggest that isoPGE2 enhances
osteoclastic differentiation of marrow preosteoclasts and that this
regulation occurs via the cAMP-dependent protein kinase pathway.
*
This work was supported by Grants HL30568 and HL/AR69261
from the National Institutes of Health and by the Cohen and Laubisch Funds.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom all correspondence should be addressed: Div. of Cardiology,
UCLA School of Medicine, 47-123 Center for the Health Sciences, 10833 Le Conte Ave., Los Angeles, CA 90095-1679. Tel.: 310-794-7105; Fax:
310-825-4963; E-mail: ytintut@ucla.edu.
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Z. Xu, M. A. Hurchla, H. Deng, O. Uluckan, F. Bu, A. Berdy, M. C. Eagleton, E. A. Heller, D. H. Floyd, W. P. Dirksen, et al.
Interferon-{gamma} Targets Cancer Cells and Osteoclasts to Prevent Tumor-associated Bone Loss and Bone Metastases
J. Biol. Chem.,
February 13, 2009;
284(7):
4658 - 4666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. N. Somayaji, S. Ritchie, M. Sahraei, I. Marriott, and M. C. Hudson
Staphylococcus aureus Induces Expression of Receptor Activator of NF-{kappa}B Ligand and Prostaglandin E2 in Infected Murine Osteoblasts
Infect. Immun.,
November 1, 2008;
76(11):
5120 - 5126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. V. Oskolkova, T. Afonyushkin, A. Leitner, E. von Schlieffen, P. S. Gargalovic, A. J. Lusis, B. R. Binder, and V. N. Bochkov
ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein response
Blood,
July 15, 2008;
112(2):
330 - 339.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. C. Poulsen, P. J. Moughan, and M. C. Kruger
Long-Chain Polyunsaturated Fatty Acids and the Regulation of Bone Metabolism
Experimental Biology and Medicine,
November 1, 2007;
232(10):
1275 - 1288.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Hirbe, J. Rubin, O. Uluckan, E. A. Morgan, M. C. Eagleton, J. L. Prior, D. Piwnica-Worms, and K. N. Weilbaecher
Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone
PNAS,
August 28, 2007;
104(35):
14062 - 14067.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Huang, S. Morony, J. Lu, Z. Zhang, O. Bezouglaia, W. Tseng, S. Tetradis, L. L. Demer, and Y. Tintut
Atherogenic Phospholipids Attenuate Osteogenic Signaling by BMP-2 and Parathyroid Hormone in Osteoblasts
J. Biol. Chem.,
July 20, 2007;
282(29):
21237 - 21243.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Hirbe, O. Uluckan, E. A. Morgan, M. C. Eagleton, J. L. Prior, D. Piwnica-Worms, K. Trinkaus, A. Apicelli, and K. Weilbaecher
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner
Blood,
April 15, 2007;
109(8):
3424 - 3431.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Li, K. P. Mouillesseaux, D. Montoya, D. Cruz, N. Gharavi, M. Dun, L. Koroniak, and J. A. Berliner
Identification of Prostaglandin E2 Receptor Subtype 2 As a Receptor Activated by OxPAPC
Circ. Res.,
March 17, 2006;
98(5):
642 - 650.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Corwin, T. J. Hartman, S. A. Maczuga, and B. I. Graubard
Dietary Saturated Fat Intake Is Inversely Associated with Bone Density in Humans: Analysis of NHANES III
J. Nutr.,
January 1, 2006;
136(1):
159 - 165.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Take, Y. Kobayashi, Y. Yamamoto, H. Tsuboi, T. Ochi, S. Uematsu, N. Okafuji, S. Kurihara, N. Udagawa, and N. Takahashi
Prostaglandin E2 Strongly Inhibits Human Osteoclast Formation
Endocrinology,
December 1, 2005;
146(12):
5204 - 5214.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Kobayashi, I. Take, T. Yamashita, T. Mizoguchi, T. Ninomiya, T. Hattori, S. Kurihara, H. Ozawa, N. Udagawa, and N. Takahashi
Prostaglandin E2 Receptors EP2 and EP4 Are Down-regulated during Differentiation of Mouse Osteoclasts from Their Precursors
J. Biol. Chem.,
June 24, 2005;
280(25):
24035 - 24042.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Kobayashi, T. Mizoguchi, I. Take, S. Kurihara, N. Udagawa, and N. Takahashi
Prostaglandin E2 Enhances Osteoclastic Differentiation of Precursor Cells through Protein Kinase A-dependent Phosphorylation of TAK1
J. Biol. Chem.,
March 25, 2005;
280(12):
11395 - 11403.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Tintut, S. Morony, and L. L. Demer
Hyperlipidemia Promotes Osteoclastic Potential of Bone Marrow Cells Ex Vivo
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2004;
24(2):
e6 - 10.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
L. L. Demer and Y. Tintut
Mineral Exploration: Search for the Mechanism of Vascular Calcification and Beyond: The 2003 Jeffrey M. Hoeg Award Lecture
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2003;
23(10):
1739 - 1743.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Weber and L. M. Markillie
Regulation of Activator Protein-1 by 8-iso-Prostaglandin E2 in a Thromboxane A2 Receptor-Dependent and -Independent Manner
Mol. Pharmacol.,
May 1, 2003;
63(5):
1075 - 1081.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|